ReviewAmerican journal of nuclear medicine and molecular imaging2014
Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.
Review in American journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Metabolic Glycoengineering Enables Fluorine-18 Radiolabeling of T Lymphocytes via Dual-Bioorthogonal Chemistry.Bioconjugate chemistry · 2026Article
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging.Npj imaging · 2025Review
- In Vitro and In Vivo Radiotoxicity and Biodistribution of Thallium-201 Delivered to Cancer Cells by Prussian Blue Nanoparticles.ACS applied materials & interfaces · 2025Article
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET.EJNMMI radiopharmacy and chemistry · 2024Article
- Article
- Radiochemistry for positron emission tomography.Nature communications · 2023Review
- Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging.Molecular pharmaceutics · 2022Article
- Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications.Molecules (Basel, Switzerland) · 2021Review
- Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography.Journal of clinical medicine · 2021Review
- A pretargeting nanoplatform for imaging and enhancing anti-inflammatory drug delivery.Bioactive materials · 2020Article
- Activatable cell-penetrating peptides: 15 years of research.RSC chemical biology · 2020Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery.Chemical science · 2020Article
- Radiometal-Containing Aryl Diazonium Salts for Chemoselective Bioconjugation of Tyrosine Residues.ACS omega · 2019Article
- Nitrone-Modified Gold Nanoparticles: Synthesis, Characterization, and Their Potential asACS omega · 2019Article
- Therapeutic Applications of Pretargeting.Pharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Due to their rapid and highly selective nature, bioorthogonal chemistry reactions are attracting a significant amount of recent interest in the radiopharmaceutical community. Over the last few years, reactions of this type have found tremendous utility in the construction of new radiopharmaceuticals and as a method of bioconjugation. Furthermore, reports are beginning to emerge in which these reactions are also being applied in vivo to facilitate a novel pretargeting strategy for the imaging and therapy of cancer. The successful implementation of such an approach could lead to dramatic improvements in image quality, therapeutic index, and reduced radiation dose to non-target organs and tissues. This review will focus on the potential of various bioorthogonal chemistry reactions to be used successfully in such an approach.
Indexed as
Identifiers
24753979PMC3992206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.